Search

Your search keyword '"George, Aaron"' showing total 536 results
Start Over Author "George, Aaron"

Refine your results

more »

more »

more »

more »

more »

more »
536 results on '"George, Aaron"'

101. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Author

Peyrin-Biroulet, Laurent, primary, Hart, Ailsa, additional, Bossuyt, Peter, additional, Long, Millie, additional, Allez, Matthieu, additional, Juillerat, Pascal, additional, Armuzzi, Alessandro, additional, Loftus, Edward V, additional, Ostad-Saffari, Elham, additional, Scalori, Astrid, additional, Oh, Young S, additional, Tole, Swati, additional, Chai, Akiko, additional, Pulley, Jennifer, additional, Lacey, Stuart, additional, Sandborn, William J, additional, Aguilar, Humberto, additional, Ahmad, Tariq, additional, Akriviadis, Evangelos, additional, Aldeguer Mante, Xavier, additional, Altorjay, Istvan, additional, Ananthakrishnan, Ashwin, additional, Andersen, Vibeke, additional, Andreu Garcia, Montserrat, additional, Aumais, Guy, additional, Avni-Biron, Irit, additional, Axler, Jeffrey, additional, Ayub, Kamran, additional, Baert, Filip, additional, Bafutto, Mauro, additional, Bamias, George, additional, Bassan, Isaac, additional, Baum, Curtis, additional, Beaugerie, Laurent, additional, Behm, Brian, additional, Bekal, Pradeep, additional, Bennett, Michael, additional, Bermejo San Jose, Fernando, additional, Bernstein, Charles, additional, Bettenworth, Dominik, additional, Bhaskar, Sudhir, additional, Biancone, Livia, additional, Bilir, Bahri, additional, Blaeker, Michael, additional, Bloom, Stuart, additional, Bohman, Verle, additional, Bosques Padilla, Francisco Javier, additional, Bouhnik, Yoram, additional, Bouma, Gerd, additional, Bourdages, Raymond, additional, Brand, Stephan, additional, Bressler, Brian, additional, Brückner, Markus, additional, Buening, Carsten, additional, Carbonnel, Franck, additional, Caves, Thomas, additional, Chapman, Jonathon, additional, Cheon, Jae Hee, additional, Chiba, Naoki, additional, Chioncel, Camelia, additional, Christodoulou, Dimitrios, additional, Clodi, Martin, additional, Cohen, Albert, additional, Corazza, Gino Roberto, additional, Corlin, Richard, additional, Cosintino, Rocco, additional, Cummings, Fraser, additional, Dalal, Robin, additional, Danese, Silvio, additional, De Maeyer, Marc, additional, De Magalhães Francesconi, Carlos Fernando, additional, De Silva, Aminda, additional, Debinski, Henry, additional, Desreumaux, Pierre, additional, Dewit, Olivier, additional, D'Haens, Geert, additional, Di Felice Boratto, Sandra, additional, Ding, John Nik, additional, Dixon, Tyler, additional, Dryden, Gerald, additional, Du Vall, George Aaron, additional, Ebert, Matthias, additional, Echarri Piudo, Ana, additional, Ehehalt, Robert, additional, Elkhashab, Magdy, additional, Ennis, Craig, additional, Etzel, Jason, additional, Fallingborg, Jan, additional, Feagan, Brian, additional, Fejes, Roland, additional, Ferraz de Campos Mazo, Daniel, additional, Ferreira de Almeida Borges, Valéria, additional, Fischer, Andreas, additional, Fixelle, Alan, additional, Fleisher, Mark, additional, Fowler, Sharyle, additional, Freilich, Bradley, additional, Friedenberg, Keith, additional, Fries, Walter, additional, Fulop, Csaba, additional, Fumery, Mathurin, additional, Fuster, Sergio, additional, G Kiss, Gyula, additional, Garcia Lopez, Santiago, additional, Gassner, Sonja, additional, Gill, Kanwar, additional, Gilletta de Saint Joseph, Cyrielle, additional, Ginsburg, Philip, additional, Gionchetti, Paolo, additional, Goldin, Eran, additional, Goldis, Adrian-Eugen, additional, Gomez Jaramillo, Hector Alejandro, additional, Gonciarz, Maciej, additional, Gordon, Glenn, additional, Green, Daniel, additional, Grimaud, Jean-Charles, additional, Guajardo Rodriguez, Rogelio, additional, Gurzo, Zoltan, additional, Gutierrez, Alexandra, additional, Gyökeres, Tibor, additional, Hahm, Ki Baik, additional, Hanauer, Stephen, additional, Hanson, John, additional, Harlan III, William, additional, Hasselblatt, Peter, additional, Hayee, Buhussain, additional, Hebuterne, Xavier, additional, Hendy, Peter, additional, Heyman, Melvin, additional, Higgins, Peter, additional, Hilal, Raouf, additional, Hindryckx, Pieter, additional, Hoentjen, Frank, additional, Hoffmann, Peter, additional, Holtkamp-Endemann, Frank, additional, Holtmann, Gerald, additional, Horvat, Gyula, additional, Howaldt, Stefanie, additional, Huber, Samuel, additional, Ibegbu, Ikechukwu, additional, Iborra Colomino, Maria Isabel, additional, Irving, Peter, additional, Isaacs, Kim, additional, Jagarlamudi, Kiran, additional, Jain, Rajesh, additional, Jankiel Miszputen, Sender, additional, Jansen, Jeroen, additional, Jones, Jennifer, additional, Karagiannis, John, additional, Karyotakis, Nicholas, additional, Kaser, Arthur, additional, Katz, Lior, additional, Katz, Seymour, additional, Katz, Leo, additional, Kaur, Nirmal, additional, Kazenaite, Edita, additional, Khanna, Reena, additional, Khurana, Sunil, additional, Kim, Joo Sung, additional, Kim, Young-Ho, additional, Kim, Sung Kook, additional, Kim, Dongwoo, additional, Klaus, Jochen, additional, Kleczkowski, Dariusz, additional, Kohout, Pavel, additional, Korczowski, Bartosz, additional, Kouklakis, Georgios, additional, Koutroubakis, Ioannis, additional, Krause, Richard, additional, Kristof, Tunde, additional, Kronborg, Ian, additional, Krummenerl, Annette, additional, Kupcinskas, Limas, additional, Laborda Molteni, Jorge, additional, Laharie, David, additional, Lahat-zok, Adi, additional, Lee, Jonghun, additional, Lee, Kang-Moon, additional, Leong, Rupert, additional, Levine, Henry, additional, Limdi, Jimmy, additional, Lindsay, James, additional, Lodhia, Nilesh, additional, Loftus, Edward, additional, Longman, Randy, additional, Lopez Serrano, Pilar, additional, Louis, Edouard, additional, Louzada Pereira, Maria Helena, additional, Lowe, John, additional, Lueth, Stefan, additional, Lukas, Milan, additional, Maconi, Giovanni, additional, Macrae, Finlay, additional, Madi-Szabo, Laszlo, additional, Mahadevan-Velayos, Uma, additional, Malluta, Everson Fernando, additional, Mana, Fazia, additional, Mannon, Peter, additional, Mantzaris, Gerasimos, additional, Marin Jimenez, Ignacio, additional, Martin Arranz, Maria Dolores, additional, Mateescu, Radu-Bogdan, additional, Mazzoleni, Felipe, additional, Meder, Agnieszka, additional, Melzer, Ehud, additional, Mertens, Jessica, additional, Mimidis, Konstantinos, additional, Mitchell, Brent, additional, Molnar, Tamas, additional, Moore, Gregory, additional, Morales Garza, Luis Alonso, additional, Mountifield, Reme, additional, Muls, Vinciane, additional, Murray, Charles, additional, Nagy, Bela, additional, Neurath, Markus, additional, Nguyen, Augustin, additional, Panaccione, Remo, additional, Pandak, William, additional, Panes Diaz, Julian, additional, Park, Jihye, additional, Pastorelli, Luca, additional, Patel, Bhaktasharan, additional, Peck-Radosavljevic, Markus, additional, Pecsi, Gyula, additional, Peerani, Farhad, additional, Perez Gisbert, Javier, additional, Pesta, Martin, additional, Petryka, Robert, additional, Peyrin-Biroulet, Laurent, additional, Phillips, Raymond, additional, Pierik, Marieke, additional, Pratha, Vijayalakshmi, additional, Prochazka, Vlastimil, additional, Racz, Istvan, additional, Radford-Smith, Graham, additional, Ramos Castañeda, Daniel, additional, Ramos Júnior, Odery, additional, Regula, Jaroslaw, additional, Reimund, Jean-Marie, additional, Robbins, Bryan, additional, Roblin, Xavier, additional, Rogai, Francesca, additional, Rogler, Gerhard, additional, Rozciecha, Jerzy, additional, Rubin, David, additional, Ruiz Flores, Azalia Yuriria, additional, Rupinski, Maciej, additional, Rydzewska, Grazyna, additional, Saha, Sumona, additional, Saibeni, Simone, additional, Salamon, Agnes, additional, Sallo, Zoltan, additional, Salzberg, Bruce, additional, Samuel, Douglas, additional, Samuel, Sunil, additional, Sandborn, William, additional, Savarino, Edoardo Vincenzo, additional, Schirbel, Anja, additional, Schnabel, Robert, additional, Schreiber, Stefan, additional, Scott, John, additional, Sedghi, Shahriar, additional, Seibold, Frank, additional, Seidelin, Jakob, additional, Seidler, Ursula, additional, Shaban, Ahmad, additional, Shafran, Ira, additional, Sheikh, Aasim, additional, Sherman, Alex, additional, Shirin, Haim, additional, Smolinski, Patryk, additional, Song, Geun Am, additional, Soufleris, Konstantinos, additional, Speight, Alexander, additional, Staessen, Dirk, additional, Stallmach, Andreas, additional, Staun, Michael, additional, Stein, Daniel, additional, Steinhart, Hillary, additional, Stifft, Jonathas, additional, Stokesberry, David, additional, Sturm, Andreas, additional, Sultan, Keith, additional, Szekely, Gyorgy, additional, Tagore, Kuldeep, additional, Tanno, Hugo, additional, Thin, Lena, additional, Thiwan, Syed, additional, Thomas, Carlton, additional, Tichy, Michal, additional, Toth, Gabor Tamas, additional, Tulassay, Zsolt, additional, Ulbrych, Jan, additional, Valentine, John, additional, Varga, Marta, additional, Vasconcellos, Eduardo, additional, Vaughn, Byron, additional, Velasco, Brenda, additional, Velazquez, Francisco, additional, Vermeire, Severine, additional, Villa, Erica, additional, Vincze, Aron, additional, Vogelsang, Harald, additional, Volfova, Miroslava, additional, Vuitton, Lucine, additional, Vyhnalek, Petr, additional, Wahab, Peter, additional, Walldorf, Jens, additional, Waterman, Mattitiahu, additional, Weber, John, additional, Weiss, L. Michael, additional, Wiechowska-Kozlowska, Anna, additional, Wiesner, Elise, additional, Witthoeft, Thomas, additional, Wohlman, Robert, additional, Wozniak-Stolarska, Barbara, additional, Yacyshyn, Bruce, additional, Ye, Byong-Duk, additional, Younes, Ziad, additional, Yukie Sassaki, Lígia, additional, Zaltman, Cyrla, additional, and Zeuzem, Stefan, additional

Published
2022
Full Text
View/download PDF

103. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Author

Laurent Peyrin-Biroulet, Ailsa Hart, Peter Bossuyt, Millie Long, Matthieu Allez, Pascal Juillerat, Alessandro Armuzzi, Edward V Loftus, Elham Ostad-Saffari, Astrid Scalori, Young S Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Stuart Lacey, William J Sandborn, Humberto Aguilar, Tariq Ahmad, Evangelos Akriviadis, Xavier Aldeguer Mante, Istvan Altorjay, Ashwin Ananthakrishnan, Vibeke Andersen, Montserrat Andreu Garcia, Guy Aumais, Irit Avni-Biron, Jeffrey Axler, Kamran Ayub, Filip Baert, Mauro Bafutto, George Bamias, Isaac Bassan, Curtis Baum, Laurent Beaugerie, Brian Behm, Pradeep Bekal, Michael Bennett, Fernando Bermejo San Jose, Charles Bernstein, Dominik Bettenworth, Sudhir Bhaskar, Livia Biancone, Bahri Bilir, Michael Blaeker, Stuart Bloom, Verle Bohman, Francisco Javier Bosques Padilla, Yoram Bouhnik, Gerd Bouma, Raymond Bourdages, Stephan Brand, Brian Bressler, Markus Brückner, Carsten Buening, Franck Carbonnel, Thomas Caves, Jonathon Chapman, Jae Hee Cheon, Naoki Chiba, Camelia Chioncel, Dimitrios Christodoulou, Martin Clodi, Albert Cohen, Gino Roberto Corazza, Richard Corlin, Rocco Cosintino, Fraser Cummings, Robin Dalal, Silvio Danese, Marc De Maeyer, Carlos Fernando De Magalhães Francesconi, Aminda De Silva, Henry Debinski, Pierre Desreumaux, Olivier Dewit, Geert D'Haens, Sandra Di Felice Boratto, John Nik Ding, Tyler Dixon, Gerald Dryden, George Aaron Du Vall, Matthias Ebert, Ana Echarri Piudo, Robert Ehehalt, Magdy Elkhashab, Craig Ennis, Jason Etzel, Jan Fallingborg, Brian Feagan, Roland Fejes, Daniel Ferraz de Campos Mazo, Valéria Ferreira de Almeida Borges, Andreas Fischer, Alan Fixelle, Mark Fleisher, Sharyle Fowler, Bradley Freilich, Keith Friedenberg, Walter Fries, Csaba Fulop, Mathurin Fumery, Sergio Fuster, Gyula G Kiss, Santiago Garcia Lopez, Sonja Gassner, Kanwar Gill, Cyrielle Gilletta de Saint Joseph, Philip Ginsburg, Paolo Gionchetti, Eran Goldin, Adrian-Eugen Goldis, Hector Alejandro Gomez Jaramillo, Maciej Gonciarz, Glenn Gordon, Daniel Green, Jean-Charles Grimaud, Rogelio Guajardo Rodriguez, Zoltan Gurzo, Alexandra Gutierrez, Tibor Gyökeres, Ki Baik Hahm, Stephen Hanauer, John Hanson, William Harlan III, Peter Hasselblatt, Buhussain Hayee, Xavier Hebuterne, Peter Hendy, Melvin Heyman, Peter Higgins, Raouf Hilal, Pieter Hindryckx, Frank Hoentjen, Peter Hoffmann, Frank Holtkamp-Endemann, Gerald Holtmann, Gyula Horvat, Stefanie Howaldt, Samuel Huber, Ikechukwu Ibegbu, Maria Isabel Iborra Colomino, Peter Irving, Kim Isaacs, Kiran Jagarlamudi, Rajesh Jain, Sender Jankiel Miszputen, Jeroen Jansen, Jennifer Jones, John Karagiannis, Nicholas Karyotakis, Arthur Kaser, Lior Katz, Seymour Katz, Leo Katz, Nirmal Kaur, Edita Kazenaite, Reena Khanna, Sunil Khurana, Joo Sung Kim, Young-Ho Kim, Sung Kook Kim, Dongwoo Kim, Jochen Klaus, Dariusz Kleczkowski, Pavel Kohout, Bartosz Korczowski, Georgios Kouklakis, Ioannis Koutroubakis, Richard Krause, Tunde Kristof, Ian Kronborg, Annette Krummenerl, Limas Kupcinskas, Jorge Laborda Molteni, David Laharie, Adi Lahat-zok, Jonghun Lee, Kang-Moon Lee, Rupert Leong, Henry Levine, Jimmy Limdi, James Lindsay, Nilesh Lodhia, Edward Loftus, Randy Longman, Pilar Lopez Serrano, Edouard Louis, Maria Helena Louzada Pereira, John Lowe, Stefan Lueth, Milan Lukas, Giovanni Maconi, Finlay Macrae, Laszlo Madi-Szabo, Uma Mahadevan-Velayos, Everson Fernando Malluta, Fazia Mana, Peter Mannon, Gerasimos Mantzaris, Ignacio Marin Jimenez, Maria Dolores Martin Arranz, Radu-Bogdan Mateescu, Felipe Mazzoleni, Agnieszka Meder, Ehud Melzer, Jessica Mertens, Konstantinos Mimidis, Brent Mitchell, Tamas Molnar, Gregory Moore, Luis Alonso Morales Garza, Reme Mountifield, Vinciane Muls, Charles Murray, Bela Nagy, Markus Neurath, Augustin Nguyen, Remo Panaccione, William Pandak, Julian Panes Diaz, Jihye Park, Luca Pastorelli, Bhaktasharan Patel, Markus Peck-Radosavljevic, Gyula Pecsi, Farhad Peerani, Javier Perez Gisbert, Martin Pesta, Robert Petryka, Raymond Phillips, Marieke Pierik, Vijayalakshmi Pratha, Vlastimil Prochazka, Istvan Racz, Graham Radford-Smith, Daniel Ramos Castañeda, Odery Ramos Júnior, Jaroslaw Regula, Jean-Marie Reimund, Bryan Robbins, Xavier Roblin, Francesca Rogai, Gerhard Rogler, Jerzy Rozciecha, David Rubin, Azalia Yuriria Ruiz Flores, Maciej Rupinski, Grazyna Rydzewska, Sumona Saha, Simone Saibeni, Agnes Salamon, Zoltan Sallo, Bruce Salzberg, Douglas Samuel, Sunil Samuel, William Sandborn, Edoardo Vincenzo Savarino, Anja Schirbel, Robert Schnabel, Stefan Schreiber, John Scott, Shahriar Sedghi, Frank Seibold, Jakob Seidelin, Ursula Seidler, Ahmad Shaban, Ira Shafran, Aasim Sheikh, Alex Sherman, Haim Shirin, Patryk Smolinski, Geun Am Song, Konstantinos Soufleris, Alexander Speight, Dirk Staessen, Andreas Stallmach, Michael Staun, Daniel Stein, Hillary Steinhart, Jonathas Stifft, David Stokesberry, Andreas Sturm, Keith Sultan, Gyorgy Szekely, Kuldeep Tagore, Hugo Tanno, Lena Thin, Syed Thiwan, Carlton Thomas, Michal Tichy, Gabor Tamas Toth, Zsolt Tulassay, Jan Ulbrych, John Valentine, Marta Varga, Eduardo Vasconcellos, Byron Vaughn, Brenda Velasco, Francisco Velazquez, Severine Vermeire, Erica Villa, Aron Vincze, Harald Vogelsang, Miroslava Volfova, Lucine Vuitton, Petr Vyhnalek, Peter Wahab, Jens Walldorf, Mattitiahu Waterman, John Weber, L. Michael Weiss, Anna Wiechowska-Kozlowska, Elise Wiesner, Thomas Witthoeft, Robert Wohlman, Barbara Wozniak-Stolarska, Bruce Yacyshyn, Byong-Duk Ye, Ziad Younes, Lígia Yukie Sassaki, Cyrla Zaltman, Stefan Zeuzem, Neurosurgery, ANS - Neurovascular Disorders, Gastroenterology and Hepatology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Peyrin-Biroulet L., Hart A., Bossuyt P., Long M., Allez M., Juillerat P., Armuzzi A., Loftus E.V., Ostad-Saffari E., Scalori A., Oh Y.S., Tole S., Chai A., Pulley J., Lacey S., Sandborn W.J., Aguilar H., Ahmad T., Akriviadis E., Aldeguer Mante X., Altorjay I., Ananthakrishnan A., Andersen V., Andreu Garcia M., Aumais G., Avni-Biron I., Axler J., Ayub K., Baert F., Bafutto M., Bamias G., Bassan I., Baum C., Beaugerie L., Behm B., Bekal P., Bennett M., Bermejo San Jose F., Bernstein C., Bettenworth D., Bhaskar S., Biancone L., Bilir B., Blaeker M., Bloom S., Bohman V., Bosques Padilla F.J., Bouhnik Y., Bouma G., Bourdages R., Brand S., Bressler B., Bruckner M., Buening C., Carbonnel F., Caves T., Chapman J., Cheon J.H., Chiba N., Chioncel C., Christodoulou D., Clodi M., Cohen A., Corazza G.R., Corlin R., Cosintino R., Cummings F., Dalal R., Danese S., De Maeyer M., De Magalhaes Francesconi C.F., De Silva A., Debinski H., Desreumaux P., Dewit O., D'Haens G., Di Felice Boratto S., Ding J.N., Dixon T., Dryden G., Du Vall G.A., Ebert M., Echarri Piudo A., Ehehalt R., Elkhashab M., Ennis C., Etzel J., Fallingborg J., Feagan B., Fejes R., Ferraz de Campos Mazo D., Ferreira de Almeida Borges V., Fischer A., Fixelle A., Fleisher M., Fowler S., Freilich B., Friedenberg K., Fries W., Fulop C., Fumery M., Fuster S., G Kiss G., Garcia Lopez S., Gassner S., Gill K., Gilletta de Saint Joseph C., Ginsburg P., Gionchetti P., Goldin E., Goldis A.-E., Gomez Jaramillo H.A., Gonciarz M., Gordon G., Green D., Grimaud J.-C., Guajardo Rodriguez R., Gurzo Z., Gutierrez A., Gyokeres T., Hahm K.B., Hanauer S., Hanson J., Harlan III W., Hasselblatt P., Hayee B., Hebuterne X., Hendy P., Heyman M., Higgins P., Hilal R., Hindryckx P., Hoentjen F., Hoffmann P., Holtkamp-Endemann F., Holtmann G., Horvat G., Howaldt S., Huber S., Ibegbu I., Iborra Colomino M.I., Irving P., Isaacs K., Jagarlamudi K., Jain R., Jankiel Miszputen S., Jansen J., Jones J., Karagiannis J., Karyotakis N., Kaser A., Katz L., Katz S., Kaur N., Kazenaite E., Khanna R., Khurana S., Kim J.S., Kim Y.-H., Kim S.K., Kim D., Klaus J., Kleczkowski D., Kohout P., Korczowski B., Kouklakis G., Koutroubakis I., Krause R., Kristof T., Kronborg I., Krummenerl A., Kupcinskas L., Laborda Molteni J., Laharie D., Lahat-zok A., Lee J., Lee K.-M., Leong R., Levine H., Limdi J., Lindsay J., Lodhia N., Loftus E., Longman R., Lopez Serrano P., Louis E., Louzada Pereira M.H., Lowe J., Lueth S., Lukas M., Maconi G., Macrae F., Madi-Szabo L., Mahadevan-Velayos U., Malluta E.F., Mana F., Mannon P., Mantzaris G., Marin Jimenez I., Martin Arranz M.D., Mateescu R.-B., Mazzoleni F., Meder A., Melzer E., Mertens J., Mimidis K., Mitchell B., Molnar T., Moore G., Morales Garza L.A., Mountifield R., Muls V., Murray C., Nagy B., Neurath M., Nguyen A., Panaccione R., Pandak W., Panes Diaz J., Park J., Pastorelli L., Patel B., Peck-Radosavljevic M., Pecsi G., Peerani F., Perez Gisbert J., Pesta M., Petryka R., Phillips R., Pierik M., Pratha V., Prochazka V., Racz I., Radford-Smith G., Ramos Castaneda D., Ramos Junior O., Regula J., Reimund J.-M., Robbins B., Roblin X., Rogai F., Rogler G., Rozciecha J., Rubin D., Ruiz Flores A.Y., Rupinski M., Rydzewska G., Saha S., Saibeni S., Salamon A., Sallo Z., Salzberg B., Samuel D., Samuel S., Sandborn W., Savarino E.V., Schirbel A., Schnabel R., Schreiber S., Scott J., Sedghi S., Seibold F., Seidelin J., Seidler U., Shaban A., Shafran I., Sheikh A., Sherman A., Shirin H., Smolinski P., Song G.A., Soufleris K., Speight A., Staessen D., Stallmach A., Staun M., Stein D., Steinhart H., Stifft J., Stokesberry D., Sturm A., Sultan K., Szekely G., Tagore K., Tanno H., Thin L., Thiwan S., Thomas C., Tichy M., Toth G.T., Tulassay Z., Ulbrych J., Valentine J., Varga M., Vasconcellos E., Vaughn B., Velasco B., Velazquez F., Vermeire S., Villa E., Vincze A., Vogelsang H., Volfova M., Vuitton L., Vyhnalek P., Wahab P., Walldorf J., Waterman M., Weber J., Weiss L.M., Wiechowska-Kozlowska A., Wiesner E., Witthoeft T., Wohlman R., Wozniak-Stolarska B., Yacyshyn B., Ye B.-D., Younes Z., Yukie Sassaki L., Zaltman C., and Zeuzem S.

Subjects
Adult, Male, Ulcerative Colitis Flare, medicine.medical_specialty, Asia, Adolescent, Oceania, Population, Antibodies, Monoclonal, Humanized, Injections, Subcutaneou, Placebo, Severity of Illness Index, law.invention, Middle East, Young Adult, Maintenance therapy, Randomized controlled trial, law, Internal medicine, Gastrointestinal Agent, medicine, Adverse effect, education, Aged, Aged, 80 and over, Tumor Necrosis Factor Inhibitor, education.field_of_study, Hepatology, business.industry, Remission Induction, Gastroenterology, Middle Aged, South America, medicine.disease, Ulcerative colitis, Europe, Treatment Outcome, Etrolizumab, North America, Colitis, Ulcerative, Female, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], Human
Abstract

Summary Background Etrolizumab is a gut-targeted, anti-β7 integrin, monoclonal antibody. In an earlier phase 2 induction study, etrolizumab significantly improved clinical remission compared with placebo in patients with moderately to severely active ulcerative colitis. We aimed to evaluate the efficacy and safety of etrolizumab in patients with moderately to severely active ulcerative colitis who had been previously treated with anti-tumour necrosis factor (TNF) agents. Methods HICKORY was a multicentre, phase 3, double-blind, placebo-controlled study in adult (18–80 years) patients with moderately to severely active ulcerative colitis (Mayo Clinic total score [MCS] of 6–12 with an endoscopic subscore of ≥2, a rectal bleeding subscore of ≥1, and a stool frequency subscore of ≥1) previously treated with TNF inhibitors. Patients were recruited from 184 treatment centres across 24 countries in North America, South America, Europe, Asia, Oceania, and the Middle East. Patients needed to have an established diagnosis of ulcerative colitis for at least 3 months, corroborated by both clinical and endoscopic evidence, and evidence of disease extending at least 20 cm from the anal verge. In cohort 1, patients received open-label etrolizumab 105 mg every 4 weeks for a 14-week induction period. In cohort 2, patients were randomly assigned (4:1) to receive subcutaneous etrolizumab 105 mg or placebo every 4 weeks for the 14-week induction phase. Patients in either cohort achieving clinical response to etrolizumab induction were eligible for the maintenance phase, in which they were randomly assigned (1:1) to receive subcutaneous etrolizumab 105 mg or placebo every 4 weeks through to week 66. Randomisation was stratified by baseline concomitant treatment with corticosteroids, concomitant treatment with immunosuppressants (induction randomisation only), baseline disease activity, week 14 MCS remission status (maintenance randomisation only), and induction cohort (maintenance randomisation only). All patients and study site personnel were masked to treatment assignment. Primary endpoints were remission (Mayo Clinic total score [MCS] ≤2, with individual subscores of ≤1 and a rectal bleeding subscore of 0) at week 14, and remission at week 66 among patients with a clinical response (MCS with ≥3-point decrease and ≥30% reduction from baseline, plus ≥1 point decrease in rectal bleeding subscore or absolute rectal bleeding score of 0 or 1) at week 14. Efficacy was analysed using a modified intent-to-treat population. Safety analyses included all patients who received at least one dose of study drug during the induction phase. This study is registered at ClinicalTrials.gov , NCT02100696 . Findings HICKORY was conducted from May 21, 2014, to April 16, 2020, during which time 1081 patients were screened, and 609 deemed eligible for inclusion. 130 patients were included in cohort 1. In cohort 2,479 patients were randomly assigned to the induction phase (etrolizumab n=384, placebo n=95). 232 patients were randomly assigned to the maintenance phase (etrolizumab to etrolizumab n=117, etrolizumab to placebo n=115). At week 14, 71 (18·5%) of 384 patients in the etrolizumab group and six (6·3%) of 95 patients in the placebo group achieved the primary induction endpoint of remission (p=0·0033). No significant difference between etrolizumab and placebo was observed for the primary maintenance endpoint of remission at week 66 among patients with a clinical response at week 14 (27 [24·1%] of 112 vs 23 [20·2%] of 114; p=0·50). Four patients in the etrolizumab group reported treatment-related adverse events leading to treatment discontinuation. The proportion of patients reporting at least adverse event was similar between treatment groups for induction (etrolizumab 253 [66%] of 384; placebo 63 [66%] of 95) and maintenance (etrolizumab to etrolizumab 98 [88%] of 112; etrolizumab to placebo 97 [85%] of 114). The most common adverse event in both groups was ulcerative colitis flare. Most adverse events were mild or moderate. During induction, the most common serious adverse event was ulcerative colitis flare (etrolizumab ten [3%] of 384; placebo: two [2%] of 95). During maintenance, the most common serious adverse event in the etrolizumab to etrolizumab group was appendicitis (two [2%] of 112) and the most common serious adverse events in the etrolizumab to placebo group were ulcerative colitis flare (two [2%] of 114) and anaemia (two [2%] of 114). Interpretation HICKORY demonstrated that a significantly higher proportion of patients with moderately to severely active ulcerative colitis who had been previously treated with anti-TNF agent were able to achieve remission at week 14 when treated with etrolizumab compared with placebo; however, there was no significant difference between groups in remission at week 66 among patients with a clinical response at week 14. Funding F Hoffmann-La Roche.

Published
2022

104. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study

Author

Severine Vermeire, Peter L Lakatos, Timothy Ritter, Stephen Hanauer, Brian Bressler, Reena Khanna, Kim Isaacs, Saumin Shah, Alysha Kadva, Helen Tyrrell, Young S Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Christopher Eden, Wenhui Zhang, Brian G Feagan, Philip Abraham, Mauro Acir Crippa Júnior, Humberto Aguilar, Tasneem Ahmed, Istvan Altorjay, Vibeke Andersen, Ronen Arai, Hays Arnold, Karlee Ausk, Jeffrey Axler, Kamran Ayub, Avinash Balekuduru, Guerino Barbalaco Neto, Isaac Bassan, Brian Behm, Pradeep Bekal, Shobna Bhatia, Barnabas Bod, Carlos Eduardo Brandão Mello, Julia Brandeburova, Johannes Breedt, Ivan Chopey, Michael Connor, Richard Corlin, Carlos Alejandro Cortez Hernandez, Arijit De, Alexander de Sá Rolim, Sandra Di Felice Boratto, Tyler Dixon, Debora Dourado Poli, David Dresner, George Aaron Du Vall, Matthias Ebert, Robert Ehehalt, Atilla Ertan, Ruben Escarcega Valencia, Jason Etzel, Jan Fallingborg, Brian Feagan, Miroslav Fedurco, Enrique Fernandez Castro, Valéria Ferreira de Almeida Borges, Mark Finklestein, Andreas Fischer, Mark Fleisher, Angel Ricardo Flores Rendon, Ronald Fogel, Osvaldo Franceschi Junior, Curtis Freedland, David Gatof, Kanwar Gill, Henning Glerup, Vardaraj Gokak, Eran Goldin, Hector Alejandro Gomez Jaramillo, Nitin Gupta, Zoltan Gurzo, Olga Gyrina, Mohammed Aejaz Habeeb, Robert Hardi, William Harlan, Ammar Hemaidan, Melvin Heyman, Peter Hoffmann, William Holderman, Frank Holtkamp-Endemann, Gyula Horvat, Eran Israeli, Sender Jankiel Miszputen, Søren Jensen, Kenneth Johnson, Jennifer Jones, Osvaldo Junior, Barbora Kadleckova, Mukesh Kalla, Zsuzsanna Kallo, Nicholas Karyotakis, Lior Katz, Leo Katz, Nirmal Kaur, Pavel Kohout, Peter Lakatos, Emmanuel Larriva de los Reyes, Robert Lee, Bernard Leman, Olena Levchenko, Henry Levine, Lúcia Libanez Bessa Campelo Braga, Edward Loftus, Tetiana Lohdanidi, Randy Longman, Josefina Lozano, Christian Maaser, Laszlo Madi-Szabo, Everson Fernando Malluta, John Marshall, Francisca Martinez Silva, Kenneth Maynard, Agnieszka Meder, Chetan Mehta, Peter Minarik, Joachim Mueller, Shrikant Mukewar, Bela Nagy, Vasyl Neiko, Markus Neurath, Brian Nichol, James Novick, Nitin Pai, William Pandak, Sarat Panigrahi, Ulrich-Frank Pape, Raymundo Paraná, Nimisha Parekh, Bhaktasharan Patel, Gyula Pecsi, Sergio Peralta, Martin Pesta, Eva Peterfai, Carlo Petruzzellis, Robert Petryka, Roberta Pica, Carlos Piniella, Vijayalakshmi Pratha, Vlastimil Prochazka, Sergey Prokopchuk, Ludmyla Prystupa, Amarender Puri, Tova Rainis, Bhashyakarla Ramesh Kumar, Odery Ramos Júnior, Iaroslava Rishko, Bryan Robbins, Elizabeth Rock, Marcelo Rodrigues Borba, Miguel Rodriguez, Jerzy Rozciecha, Azalia Yuriria Ruiz Flores, Grazyna Rydzewska, Rifaat Safadi, Simone Saibeni, Anja Schirbel, Wolff Schmiegel, Róbert Schnabel, Herbert Schneider, Armando Segui, Jakob Seidelin, Ursula Seidler, Joseph Sellin, Ira Shafran, Aasim Sheikh, Alex Sherman, Haim Shirin, Akash Shukla, Firdous Siddiqui, Robert Sike, Ajit Sood, Andreas Stallmach, Mykola Stanislavchuk, Michael Staun, Daniel Stein, Alon Steinberg, Hillary Steinhart, Jonathas Stifft, Rakesh Tandon, Vishwanath Tantry, Syed Thiwan, Matthias Treiber, Jan Ulbrych, John Valentine, Rajeev Vasudeva, Byron Vaughn, Brenda Velasco, Aron Vincze, Miroslava Volfova, Mattitiahu Waterman, L. Michael Weiss, Elise Wiesner, Alonzo Williams, Thomas Witthoeft, Robert Wohlman, John Wright, Jesus Kazuo Yamamoto Furusho, Ziad Younes, Khurshid Yousuf, Yaroslav Zborivskyy, Stefan Zeuzem, and Vyacheslav Zhdan

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Population, Phases of clinical research, Placebo, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Maintenance Chemotherapy, Young Adult, Maintenance therapy, Double-Blind Method, Gastrointestinal Agents, Internal medicine, Clinical endpoint, Medicine, Humans, education, Adverse effect, Aged, education.field_of_study, Science & Technology, Hepatology, Gastroenterology & Hepatology, business.industry, Remission Induction, Gastroenterology, Colonoscopy, Middle Aged, medicine.disease, Symptom Flare Up, Ulcerative colitis, Etrolizumab, Colitis, Ulcerative, Female, business, Life Sciences & Biomedicine
Abstract

BACKGROUND: Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a previous phase 2 induction study, etrolizumab significantly improved clinical remission versus placebo in patients with moderately to severely active ulcerative colitis. We aimed to evaluate the efficacy and safety of etrolizumab for maintenance of remission in patients with moderately to severely active ulcerative colitis. METHODS: We conducted a randomised, placebo-controlled, double-blind, phase 3 study (LAUREL) across 111 treatment centres worldwide. We included adults (age 18-80 years) with moderately to severely active ulcerative colitis (Mayo Clinic total score [MCS] of 6-12 with an endoscopic subscore of ≥2, a rectal bleeding subscore of ≥1, and a stool frequency subscore of ≥1) who were naive to tumour necrosis factor inhibitors. Patients were required to have had an established diagnosis of ulcerative colitis for at least 3 months, corroborated by both clinical and endoscopic evidence, and evidence of disease extending at least 20 cm from the anal verge. During open-label induction, participants received subcutaneous etrolizumab 105 mg once every 4 weeks. Participants who had clinical response at week 10 (MCS with ≥3-point decrease and ≥30% reduction from baseline, plus ≥1-point decrease in rectal bleeding subscore or absolute rectal bleeding score of 0 or 1) proceeded into the double-blind maintenance phase and were randomly assigned (1:1) to receive subcutaneous etrolizumab 105 mg once every 4 weeks or matched placebo until week 62. Randomisation was stratified by baseline concomitant treatment with corticosteroids, treatment with immunosuppressants, baseline disease activity, and week 10 remission status. All participants and study site personnel were masked to treatment assignment. The primary endpoint was remission at week 62 (MCS ≤2, with individual subscores ≤1, and rectal bleeding subscore of 0) among patients with a clinical response at week 10, measured in the modified intention-to-treat population (all randomised patients who received at least one dose of study drug). This trial is registered with ClinicalTrials.gov, NCT02165215, and is now closed to recruitment. FINDINGS: Between Aug 12, 2014, and June 4, 2020, 658 patients were screened for eligibility and 359 were enrolled into the induction phase. 214 (60%) patients had a clinical response at week 10 and were randomly assigned to receive etrolizumab (n=108) or placebo (n=106) in the maintenance phase. 80 (74%) patients in the etrolizumab group and 42 (40%) in the placebo group completed the study through week 62. Four patients in the placebo group did not receive study treatment and were excluded from the analyses. At week 62, 32 (29·6%) of 108 patients in the etrolizumab group and 21 (20·6%) of 102 in the placebo group were in remission (adjusted treatment difference 7·7% [95% CI -4·2 to 19·2]; p=0·19). A greater proportion of patients reported one or more adverse events in the placebo group (82 [80%] of 102) than in the etrolizumab group (70 [65%] of 108); the most common adverse event in both groups was ulcerative colitis (16 [15%] patients in the etrolizumab group and 37 [36%] in the placebo group). Ten (9%) patients in the etrolizumab group and eight (8%) in the placebo group reported one or more serious adverse events. No deaths were reported in either treatment group. INTERPRETATION: No significant differences were observed between maintenance etrolizumab and placebo in the primary endpoint of remission at week 62 among patients who had a clinical response at week 10. Etrolizumab was well tolerated in this population and no new safety signals were identified. FUNDING: F Hoffmann-La Roche. ispartof: LANCET GASTROENTEROLOGY & HEPATOLOGY vol:7 issue:1 pages:28-37 ispartof: location:Netherlands status: published

Published
2021

109. Tiamat

Author

George Aaron Barton

Published
2010

110. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials

Author

Rubin, David T, primary, Dotan, Iris, additional, DuVall, Aaron, additional, Bouhnik, Yoram, additional, Radford-Smith, Graham, additional, Higgins, Peter D R, additional, Mishkin, Daniel S, additional, Arrisi, Pablo, additional, Scalori, Astrid, additional, Oh, Young S, additional, Tole, Swati, additional, Chai, Akiko, additional, Chamberlain-James, Kirsten, additional, Lacey, Stuart, additional, McBride, Jacqueline, additional, Panés, Julian, additional, Rustem, Abdulkhakov, additional, Norasiah, Abu Bakar, additional, Humberto, Aguilar, additional, Diego, Aizenberg, additional, Hale, Akpinar, additional, Evangelos, Akriviadis, additional, Olga, Alexeeva, additional, Bagdadi, Alikhanov, additional, Andres, Alvarisqueta, additional, Ashwin, Ananthakrishnan, additional, Jane, Andrews, additional, Tomasz, Arlukowicz, additional, Nathan, Atkinson, additional, Ozlen, Atug, additional, Mauro, Bafutto, additional, Jozef, Balaz, additional, George, Bamias, additional, Marko, Banic, additional, Andrey, Baranovsky, additional, Guerino, Barbalaco Neto, additional, Metin, Basaranoglu, additional, Curtis, Baum, additional, Stefan, Baydanov, additional, William, Bennetts, additional, Fatih, Besisik, additional, Sudhir, Bhaskar, additional, Andrzej, Bielasik, additional, Leonid, Bilianskyi, additional, Bahri, Bilir, additional, Pavol, Blaha, additional, Verle, Bohman, additional, Julia, Borissova, additional, Vladimir, Borzan, additional, Francisco, Bosques-Padilla, additional, Yoram, Bouhnik, additional, James, Brooker, additional, Tetiana, Budko, additional, Igor, Budzak, additional, Ivan, Bunganic, additional, Jonathon, Chapman, additional, Azlida, Che' Aun, additional, Tatiana, Chernykh, additional, Michael, Chiorean, additional, Ivan, Chopey, additional, Dimitrios, Christodoulou, additional, Pui Shan, Chu, additional, Galina, Chumakova, additional, Andrew, Cummins, additional, Robert, Cunliffe, additional, Mirjana, Cvetkovic, additional, Ulku, Dagli, additional, Wit Cezary, Danilkiewicz, additional, Olena, Datsenko, additional, Carlos Fernando, de Magalhães Francesconi, additional, Henry, Debinski, additional, Elena, Deminova, additional, Jelena, Derova, additional, John Nik, Ding, additional, Julia, Dmitrieva, additional, Oleg, Dolgikh, additional, Tomas, Douda, additional, Piotr, Drobinski, additional, Gerald, Dryden, additional, Pedro, Duarte Gaburri, additional, George Aaron, DuVall, additional, Mikhail, Dvorkin, additional, Craig, Ennis, additional, Yusuf, Erzin, additional, Galyna, Fadieienko, additional, Oleksandr, Fediv, additional, Olga, Fedorishina, additional, Miroslav, Fedurco, additional, Roland, Fejes, additional, Jorge, Fernandez, additional, Monica Lorena, Fernandez, additional, Lucky, Flores, additional, Bradley, Freilich, additional, Keith, Friedenberg, additional, Sergio, Fuster, additional, Beata, Gawdis-Wojnarska, additional, Fabio Leonel, Gil Parada, additional, Edgardo Daniel, Gimenez, additional, Nataliia, Golovchenko, additional, Oleksandr, Golovchenko, additional, Maciej, Gonciarz, additional, Can, Gonen, additional, Glenn, Gordon, additional, Milos, Gregus, additional, Vladimir, Grinevich, additional, Rogelio, Guajardo Rodriguez, additional, Stephen, Hall, additional, John, Hanson, additional, Marek, Hartleb, additional, Xavier, Hebuterne, additional, Peter, Hendy, additional, Robert, Herring, additional, David, Hetzel, additional, Peter, Higgins, additional, Raouf, Hilal, additional, Ida Normiha, Hilmi, additional, Tibor, Hlavaty, additional, Richard, Holman, additional, Gerald, Holtmann, additional, John, Hong, additional, Frantisek, Horvath, additional, Ihor, Hospodarskyy, additional, Irena, Hrstic, additional, Sadettin, Hulagu, additional, Luis Alberto, Ibarra Verdugo, additional, Ikechukwu, Ibegbu, additional, Stephen, Inns, additional, Vladimir, Ivashkin, additional, James, Izanec, additional, Rajesh, Jain, additional, Zofia, Jamrozik-Kruk, additional, Victor, Kamburov, additional, John, Karagiannis, additional, Tarkan, Karakan, additional, Marek, Karczewski, additional, Irina, Kasherininova, additional, Seymour, Katz, additional, Barry, Kaufman, additional, Edita, Kazenaite, additional, Irina, Kholina, additional, Sunil, Khurana, additional, Jaroslaw, Kierkus, additional, Anzela, Kiselevska, additional, Dariusz, Kleczkowski, additional, Volodymyr, Klymenko, additional, Slavko, Knezevic, additional, Malgorzata, Kondusz-Szklarz, additional, Natalya, Korablina, additional, Bartosz, Korczowski, additional, Lyubomir, Kosturkov, additional, Iskren, Kotzev, additional, Georgios, Kouklakis, additional, Ioannis, Koutroubakis, additional, Richard, Krause, additional, Ian, Kronborg, additional, Miodrag, Krstic, additional, Zeljko, Krznaric, additional, Mikolaj, Krzyzanowski, additional, Grazyna, Kulig, additional, Karin, Kull, additional, Limas, Kupcinskas, additional, Mark, Lamet, additional, Tatjana, Latinovic Radakovic, additional, Rupert, Leong, additional, Wai Keung, Leung, additional, Henry, Levine, additional, Michael Kin Kong, Li, additional, Lúcia, Libanez Bessa Campelo Braga, additional, Maria, Livzan, additional, Tetiana, Lohdanidi, additional, Maria Helena, Louzada Pereira, additional, John, Lowe, additional, Kresimir, Luetic, additional, Milan, Lukas, additional, Yurii, Lymar, additional, Finlay, Macrae, additional, Anu, Mäelt, additional, Igor, Maev, additional, Arkadiusz, Mamos, additional, Gerasimos, Mantzaris, additional, Benno, Margus, additional, Ivanka, Marinova, additional, Inna, Markevych, additional, Mario, Markov, additional, Srdjan, Markovic, additional, Juan Ricardo, Marquez Velasquez, additional, Felipe, Mazzoleni, additional, Konstantinos, Mimidis, additional, Brent, Mitchell, additional, Gregory, Moore, additional, Luis Alonso, Morales Garza, additional, Salvatore, Moscatello, additional, Yuriy, Mostovoy, additional, Reme, Mountifield, additional, Aleksandar, Nagorni, additional, Viacheslav, Neshta, additional, Andrey, Obrezan, additional, Oleksandr, Oliinyk, additional, Genoile, Oliveira Santana Silva, additional, Maria, Orzeszko, additional, Vladimir, Pavlenko, additional, Dimitar, Pavlov, additional, Mariana, Penkova, additional, Sasa, Peric, additional, Plamen, Petkov, additional, Asen, Petrov, additional, Plamen, Petrov, additional, Michaela, Petrova, additional, Raymond, Phillips, additional, Sergio, Pintor Chacon, additional, Igor, Polianskyi, additional, Ludmyla, Prystupa, additional, Mykhailo, Pugach, additional, Ana Teresa, Pugas Carvalho, additional, Aldis, Pukitis, additional, Jiri, Pumprla, additional, Volodymyr, Pyrogovskyy, additional, Istvan, Racz, additional, Graham, Radford-Smith, additional, Raja Affendi, Raja Ali, additional, Daniel, Ramos Castañeda, additional, Odery, Ramos Júnior, additional, David, Rausher, additional, Andrey, Rebrov, additional, Jaroslaw, Regula, additional, Amir, Rezk, additional, Viktoriia, Reznikova, additional, Iaroslava, Rishko, additional, Xavier, Roblin, additional, Grigory, Rodoman, additional, Carlos Arturo, Rojas Rodriguez, additional, Jerzy, Rozciecha, additional, David, Rubin, additional, Maciej, Rupinski, additional, Jacek, Rzucidlo, additional, Oleg, Sablin, additional, Halil, Sahin, additional, Rosemi, Salleh, additional, Douglas, Samuel, additional, Antonio, Scafuto Scotton, additional, Robert, Schnabel, additional, Michael, Schulman, additional, Michael, Schultz, additional, John, Scott, additional, Shahriar, Sedghi, additional, Ahmad, Shaban, additional, Marina, Shapina, additional, Natalia, Shaposhnikova, additional, Oksana, Shchukina, additional, Alex, Sherman, additional, Irina, Shumikhina, additional, Vladimir, Simanenkov, additional, Vladislav, Simonov, additional, Giedrius, Simulionis, additional, Igor, Skrypnyk, additional, Zbigniew, Sliwowski, additional, Jan, Smid, additional, Mahmood, Solaiman, additional, Najm, Soofi, additional, Konstantinos, Soufleris, additional, Zoia, Spassova, additional, Mykola, Stanislavchuk, additional, Krystyna, Stec-Michalska, additional, Jonathas, Stifft, additional, Simeon, Stoinov, additional, Girgina, Stoyanova, additional, Keith, Sultan, additional, Lindsey, Surace, additional, Dimitar, Takov, additional, Jaak, Tälli, additional, Ludmila, Tankova, additional, Hugo, Tanno, additional, Dino, Tarabar, additional, Elias, Tarakji, additional, Konstantin, Tchernev, additional, Hoi Poh, Tee, additional, Lena, Thin, additional, Carlton, Thomas, additional, Irina, Tishaeva, additional, Tsveta, Todorova, additional, Oleksandr, Tokarenko, additional, Ivars, Tolmanis, additional, Ratko, Tomasevic, additional, Vasiliy, Trofimov, additional, Zsolt, Tulassay, additional, Belkis, Unsal, additional, Alma, Uzunova-Genova, additional, John, Valentine, additional, Ekaterina, Valuyskikh, additional, Eduardo, Vasconcellos, additional, Galina, Vasileva, additional, Sergiy, Vasylyuk, additional, Byron, Vaughn, additional, Francisco, Velazquez, additional, Vadym, Vizir, additional, Borislav, Vladimirov, additional, Miroslava, Volfova, additional, Petr, Vyhnalek, additional, Ian, Wallace, additional, Marek, Waluga, additional, William, Watkins, additional, John, Weber, additional, Anna, Wiechowska-Kozlowska, additional, Nathaniel, Winstead, additional, Pawel, Wojtkiewicz, additional, Barbara, Wozniak-Stolarska, additional, Bruce, Yacyshyn, additional, Alexey, Yakovlev, additional, Ziad, Younes, additional, Lígia, Yukie Sassaki, additional, Ilhami, Yuksel, additional, Jan, Zachar, additional, Cyrla, Zaltman, additional, Natasa, Zdravkovic Petrovic, additional, Vyacheslav, Zhdan, additional, Maryna, Zinchenko, additional, and Maciej, Zymla, additional

Published
2022
Full Text
View/download PDF

112. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study

Author

Vermeire, Severine, primary, Lakatos, Peter L, additional, Ritter, Timothy, additional, Hanauer, Stephen, additional, Bressler, Brian, additional, Khanna, Reena, additional, Isaacs, Kim, additional, Shah, Saumin, additional, Kadva, Alysha, additional, Tyrrell, Helen, additional, Oh, Young S, additional, Tole, Swati, additional, Chai, Akiko, additional, Pulley, Jennifer, additional, Eden, Christopher, additional, Zhang, Wenhui, additional, Feagan, Brian G, additional, Abraham, Philip, additional, Acir Crippa Júnior, Mauro, additional, Aguilar, Humberto, additional, Ahmed, Tasneem, additional, Altorjay, Istvan, additional, Andersen, Vibeke, additional, Arai, Ronen, additional, Arnold, Hays, additional, Ausk, Karlee, additional, Axler, Jeffrey, additional, Ayub, Kamran, additional, Balekuduru, Avinash, additional, Barbalaco Neto, Guerino, additional, Bassan, Isaac, additional, Behm, Brian, additional, Bekal, Pradeep, additional, Bhatia, Shobna, additional, Bod, Barnabas, additional, Brandão Mello, Carlos Eduardo, additional, Brandeburova, Julia, additional, Breedt, Johannes, additional, Chopey, Ivan, additional, Connor, Michael, additional, Corlin, Richard, additional, Cortez Hernandez, Carlos Alejandro, additional, De, Arijit, additional, de Sá Rolim, Alexander, additional, Di Felice Boratto, Sandra, additional, Dixon, Tyler, additional, Dourado Poli, Debora, additional, Dresner, David, additional, Du Vall, George Aaron, additional, Ebert, Matthias, additional, Ehehalt, Robert, additional, Ertan, Atilla, additional, Escarcega Valencia, Ruben, additional, Etzel, Jason, additional, Fallingborg, Jan, additional, Feagan, Brian, additional, Fedurco, Miroslav, additional, Fernandez Castro, Enrique, additional, Ferreira de Almeida Borges, Valéria, additional, Finklestein, Mark, additional, Fischer, Andreas, additional, Fleisher, Mark, additional, Flores Rendon, Angel Ricardo, additional, Fogel, Ronald, additional, Franceschi Junior, Osvaldo, additional, Freedland, Curtis, additional, Gatof, David, additional, Gill, Kanwar, additional, Glerup, Henning, additional, Gokak, Vardaraj, additional, Goldin, Eran, additional, Gomez Jaramillo, Hector Alejandro, additional, Gupta, Nitin, additional, Gurzo, Zoltan, additional, Gyrina, Olga, additional, Habeeb, Mohammed Aejaz, additional, Hardi, Robert, additional, Harlan, William, additional, Hemaidan, Ammar, additional, Heyman, Melvin, additional, Hoffmann, Peter, additional, Holderman, William, additional, Holtkamp-Endemann, Frank, additional, Horvat, Gyula, additional, Israeli, Eran, additional, Jankiel Miszputen, Sender, additional, Jensen, Søren, additional, Johnson, Kenneth, additional, Jones, Jennifer, additional, Junior, Osvaldo, additional, Kadleckova, Barbora, additional, Kalla, Mukesh, additional, Kallo, Zsuzsanna, additional, Karyotakis, Nicholas, additional, Katz, Lior, additional, Katz, Leo, additional, Kaur, Nirmal, additional, Kohout, Pavel, additional, Lakatos, Peter, additional, Larriva de los Reyes, Emmanuel, additional, Lee, Robert, additional, Leman, Bernard, additional, Levchenko, Olena, additional, Levine, Henry, additional, Libanez Bessa Campelo Braga, Lúcia, additional, Loftus, Edward, additional, Lohdanidi, Tetiana, additional, Longman, Randy, additional, Lozano, Josefina, additional, Maaser, Christian, additional, Madi-Szabo, Laszlo, additional, Malluta, Everson Fernando, additional, Marshall, John, additional, Martinez Silva, Francisca, additional, Maynard, Kenneth, additional, Meder, Agnieszka, additional, Mehta, Chetan, additional, Minarik, Peter, additional, Mueller, Joachim, additional, Mukewar, Shrikant, additional, Nagy, Bela, additional, Neiko, Vasyl, additional, Neurath, Markus, additional, Nichol, Brian, additional, Novick, James, additional, Pai, Nitin, additional, Pandak, William, additional, Panigrahi, Sarat, additional, Pape, Ulrich-Frank, additional, Paraná, Raymundo, additional, Parekh, Nimisha, additional, Patel, Bhaktasharan, additional, Pecsi, Gyula, additional, Peralta, Sergio, additional, Pesta, Martin, additional, Peterfai, Eva, additional, Petruzzellis, Carlo, additional, Petryka, Robert, additional, Pica, Roberta, additional, Piniella, Carlos, additional, Pratha, Vijayalakshmi, additional, Prochazka, Vlastimil, additional, Prokopchuk, Sergey, additional, Prystupa, Ludmyla, additional, Puri, Amarender, additional, Rainis, Tova, additional, Ramesh Kumar, Bhashyakarla, additional, Ramos Júnior, Odery, additional, Rishko, Iaroslava, additional, Robbins, Bryan, additional, Rock, Elizabeth, additional, Rodrigues Borba, Marcelo, additional, Rodriguez, Miguel, additional, Rozciecha, Jerzy, additional, Ruiz Flores, Azalia Yuriria, additional, Rydzewska, Grazyna, additional, Safadi, Rifaat, additional, Saibeni, Simone, additional, Schirbel, Anja, additional, Schmiegel, Wolff, additional, Schnabel, Róbert, additional, Schneider, Herbert, additional, Segui, Armando, additional, Seidelin, Jakob, additional, Seidler, Ursula, additional, Sellin, Joseph, additional, Shafran, Ira, additional, Sheikh, Aasim, additional, Sherman, Alex, additional, Shirin, Haim, additional, Shukla, Akash, additional, Siddiqui, Firdous, additional, Sike, Robert, additional, Sood, Ajit, additional, Stallmach, Andreas, additional, Stanislavchuk, Mykola, additional, Staun, Michael, additional, Stein, Daniel, additional, Steinberg, Alon, additional, Steinhart, Hillary, additional, Stifft, Jonathas, additional, Tandon, Rakesh, additional, Tantry, Vishwanath, additional, Thiwan, Syed, additional, Treiber, Matthias, additional, Ulbrych, Jan, additional, Valentine, John, additional, Vasudeva, Rajeev, additional, Vaughn, Byron, additional, Velasco, Brenda, additional, Vincze, Aron, additional, Volfova, Miroslava, additional, Waterman, Mattitiahu, additional, Weiss, L. Michael, additional, Wiesner, Elise, additional, Williams, Alonzo, additional, Witthoeft, Thomas, additional, Wohlman, Robert, additional, Wright, John, additional, Yamamoto Furusho, Jesus Kazuo, additional, Younes, Ziad, additional, Yousuf, Khurshid, additional, Zborivskyy, Yaroslav, additional, Zeuzem, Stefan, additional, and Zhdan, Vyacheslav, additional

Published
2022
Full Text
View/download PDF

117. “THIS WAS A WHITE PEOPLE’S GAME…THEY WERE THE GATEKEEPERS”: EXPERIENCES OF FRATERNITY/SORORITY PROFESSIONALS OF COLOR.

Author

GEORGE, AARON THOMAS

Subjects
GREEK letter societies, RACE, BROTHERLINESS, PEOPLE of color, GATEKEEPERS, PROFESSIONAL employees
Abstract

In this narrative inquiry, interviews from eight campus fraternity/sorority professionals who identify as people of color and who are members of culturally based fraternities and sororities were interviewed on how they experience their profession. Findings spoke to themes of guest in your own home, advocacy through presence, the complexity of representation matters, and turning burden into purpose. Overall participants spoke about caring deeply for their role given the challenges and obstacles that race and racism played and navigating systems and people that did not always value their experience. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

119. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials

Author

David T Rubin, Iris Dotan, Aaron DuVall, Yoram Bouhnik, Graham Radford-Smith, Peter D R Higgins, Daniel S Mishkin, Pablo Arrisi, Astrid Scalori, Young S Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Stuart Lacey, Jacqueline McBride, Julian Panés, Abdulkhakov Rustem, Abu Bakar Norasiah, Aguilar Humberto, Aizenberg Diego, Akpinar Hale, Akriviadis Evangelos, Alexeeva Olga, Alikhanov Bagdadi, Alvarisqueta Andres, Ananthakrishnan Ashwin, Andrews Jane, Arlukowicz Tomasz, Atkinson Nathan, Atug Ozlen, Bafutto Mauro, Balaz Jozef, Bamias George, Banic Marko, Baranovsky Andrey, Barbalaco Neto Guerino, Basaranoglu Metin, Baum Curtis, Baydanov Stefan, Bennetts William, Besisik Fatih, Bhaskar Sudhir, Bielasik Andrzej, Bilianskyi Leonid, Bilir Bahri, Blaha Pavol, Bohman Verle, Borissova Julia, Borzan Vladimir, Bosques-Padilla Francisco, Bouhnik Yoram, Brooker James, Budko Tetiana, Budzak Igor, Bunganic Ivan, Chapman Jonathon, Che' Aun Azlida, Chernykh Tatiana, Chiorean Michael, Chopey Ivan, Christodoulou Dimitrios, Chu Pui Shan, Chumakova Galina, Cummins Andrew, Cunliffe Robert, Cvetkovic Mirjana, Dagli Ulku, Danilkiewicz Wit Cezary, Datsenko Olena, de Magalhães Francesconi Carlos Fernando, Debinski Henry, Deminova Elena, Derova Jelena, Ding John Nik, Dmitrieva Julia, Dolgikh Oleg, Douda Tomas, Drobinski Piotr, Dryden Gerald, Duarte Gaburri Pedro, DuVall George Aaron, Dvorkin Mikhail, Ennis Craig, Erzin Yusuf, Fadieienko Galyna, Fediv Oleksandr, Fedorishina Olga, Fedurco Miroslav, Fejes Roland, Fernandez Jorge, Fernandez Monica Lorena, Flores Lucky, Freilich Bradley, Friedenberg Keith, Fuster Sergio, Gawdis-Wojnarska Beata, Gil Parada Fabio Leonel, Gimenez Edgardo Daniel, Golovchenko Nataliia, Golovchenko Oleksandr, Gonciarz Maciej, Gonen Can, Gordon Glenn, Gregus Milos, Grinevich Vladimir, Guajardo Rodriguez Rogelio, Hall Stephen, Hanson John, Hartleb Marek, Hebuterne Xavier, Hendy Peter, Herring Robert, Hetzel David, Higgins Peter, Hilal Raouf, Hilmi Ida Normiha, Hlavaty Tibor, Holman Richard, Holtmann Gerald, Hong John, Horvath Frantisek, Hospodarskyy Ihor, Hrstic Irena, Hulagu Sadettin, Ibarra Verdugo Luis Alberto, Ibegbu Ikechukwu, Inns Stephen, Ivashkin Vladimir, Izanec James, Jain Rajesh, Jamrozik-Kruk Zofia, Kamburov Victor, Karagiannis John, Karakan Tarkan, Karczewski Marek, Kasherininova Irina, Katz Seymour, Kaufman Barry, Kazenaite Edita, Kholina Irina, Khurana Sunil, Kierkus Jaroslaw, Kiselevska Anzela, Kleczkowski Dariusz, Klymenko Volodymyr, Knezevic Slavko, Kondusz-Szklarz Malgorzata, Korablina Natalya, Korczowski Bartosz, Kosturkov Lyubomir, Kotzev Iskren, Kouklakis Georgios, Koutroubakis Ioannis, Krause Richard, Kronborg Ian, Krstic Miodrag, Krznaric Zeljko, Krzyzanowski Mikolaj, Kulig Grazyna, Kull Karin, Kupcinskas Limas, Lamet Mark, Latinovic Radakovic Tatjana, Leong Rupert, Leung Wai Keung, Levine Henry, Li Michael Kin Kong, Libanez Bessa Campelo Braga Lúcia, Livzan Maria, Lohdanidi Tetiana, Louzada Pereira Maria Helena, Lowe John, Luetic Kresimir, Lukas Milan, Lymar Yurii, Macrae Finlay, Mäelt Anu, Maev Igor, Mamos Arkadiusz, Mantzaris Gerasimos, Margus Benno, Marinova Ivanka, Markevych Inna, Markov Mario, Markovic Srdjan, Marquez Velasquez Juan Ricardo, Mazzoleni Felipe, Mimidis Konstantinos, Mitchell Brent, Moore Gregory, Morales Garza Luis Alonso, Moscatello Salvatore, Mostovoy Yuriy, Mountifield Reme, Nagorni Aleksandar, Neshta Viacheslav, Obrezan Andrey, Oliinyk Oleksandr, Oliveira Santana Silva Genoile, Orzeszko Maria, Pavlenko Vladimir, Pavlov Dimitar, Penkova Mariana, Peric Sasa, Petkov Plamen, Petrov Asen, Petrov Plamen, Petrova Michaela, Phillips Raymond, Pintor Chacon Sergio, Polianskyi Igor, Prystupa Ludmyla, Pugach Mykhailo, Pugas Carvalho Ana Teresa, Pukitis Aldis, Pumprla Jiri, Pyrogovskyy Volodymyr, Racz Istvan, Radford-Smith Graham, Raja Ali Raja Affendi, Ramos Castañeda Daniel, Ramos Júnior Odery, Rausher David, Rebrov Andrey, Regula Jaroslaw, Rezk Amir, Reznikova Viktoriia, Rishko Iaroslava, Roblin Xavier, Rodoman Grigory, Rojas Rodriguez Carlos Arturo, Rozciecha Jerzy, Rubin David, Rupinski Maciej, Rzucidlo Jacek, Sablin Oleg, Sahin Halil, Salleh Rosemi, Samuel Douglas, Scafuto Scotton Antonio, Schnabel Robert, Schulman Michael, Schultz Michael, Scott John, Sedghi Shahriar, Shaban Ahmad, Shapina Marina, Shaposhnikova Natalia, Shchukina Oksana, Sherman Alex, Shumikhina Irina, Simanenkov Vladimir, Simonov Vladislav, Simulionis Giedrius, Skrypnyk Igor, Sliwowski Zbigniew, Smid Jan, Solaiman Mahmood, Soofi Najm, Soufleris Konstantinos, Spassova Zoia, Stanislavchuk Mykola, Stec-Michalska Krystyna, Stifft Jonathas, Stoinov Simeon, Stoyanova Girgina, Sultan Keith, Surace Lindsey, Takov Dimitar, Tälli Jaak, Tankova Ludmila, Tanno Hugo, Tarabar Dino, Tarakji Elias, Tchernev Konstantin, Tee Hoi Poh, Thin Lena, Thomas Carlton, Tishaeva Irina, Todorova Tsveta, Tokarenko Oleksandr, Tolmanis Ivars, Tomasevic Ratko, Trofimov Vasiliy, Tulassay Zsolt, Unsal Belkis, Uzunova-Genova Alma, Valentine John, Valuyskikh Ekaterina, Vasconcellos Eduardo, Vasileva Galina, Vasylyuk Sergiy, Vaughn Byron, Velazquez Francisco, Vizir Vadym, Vladimirov Borislav, Volfova Miroslava, Vyhnalek Petr, Wallace Ian, Waluga Marek, Watkins William, Weber John, Wiechowska-Kozlowska Anna, Winstead Nathaniel, Wojtkiewicz Pawel, Wozniak-Stolarska Barbara, Yacyshyn Bruce, Yakovlev Alexey, Younes Ziad, Yukie Sassaki Lígia, Yuksel Ilhami, Zachar Jan, Zaltman Cyrla, Zdravkovic Petrovic Natasa, Zhdan Vyacheslav, Zinchenko Maryna, and Zymla Maciej

Subjects
Ulcerative Colitis Flare, Adult, Male, medicine.medical_specialty, Adolescent, Population, Placebo, Antibodies, Monoclonal, Humanized, Gastroenterology, Severity of Illness Index, Placebos, Young Adult, Double-Blind Method, Gastrointestinal Agents, Internal medicine, Adalimumab, Medicine, Humans, Adverse effect, education, Aged, education.field_of_study, Hepatology, business.industry, Remission Induction, Colonoscopy, Induction Chemotherapy, Middle Aged, medicine.disease, Symptom Flare Up, Ulcerative colitis, Concomitant, Etrolizumab, Colitis, Ulcerative, Female, business, medicine.drug
Abstract

Summary Background Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In an earlier phase 2 induction study, etrolizumab significantly improved clinical remission relative to placebo in patients with moderately to severely active ulcerative colitis. The HIBISCUS studies aimed to compare the efficacy and safety of etrolizumab to adalimumab and placebo for induction of remission in patients with moderately to severely active ulcerative colitis. Methods HIBISCUS I and HIBISCUS II were identically designed, multicentre, phase 3, randomised, double-blind, placebo-controlled and active-controlled studies of etrolizumab, adalimumab, and placebo in adult (18–80 years) patients with moderately to severely active ulcerative colitis (Mayo Clinic total score [MCS] of 6–12 with an endoscopic subscore of ≥2, a rectal bleeding subscore of ≥1, and a stool frequency subscore of ≥1) who were naive to tumour necrosis factor inhibitors. All patients had an established diagnosis of ulcerative colitis for at least 3 months, corroborated by both clinical and endoscopic evidence, and evidence of disease extending at least 20 cm from the anal verge. In both studies, patients were randomly assigned (2:2:1) to receive subcutaneous etrolizumab 105 mg once every 4 weeks; subcutaneous adalimumab 160 mg on day 1, 80 mg at week 2, and 40 mg at weeks 4, 6, and 8; or placebo. Randomisation was stratified by baseline concomitant treatment with corticosteroids, concomitant treatment with immunosuppressants, and baseline disease activity. All patients and study site personnel were masked to treatment assignment. The primary endpoint was induction of remission at week 10 (defined as MCS of 2 or lower, with individual subscores of 1 or lower, and rectal bleeding subscore of 0) with etrolizumab compared with placebo. Pooled analyses of both studies comparing etrolizumab and adalimumab were examined for several clinical and endoscopic endpoints. Efficacy was analysed using a modified intent-to-treat population, defined as all randomly assigned patients who received at least one dose of study drug. These trials are registered with ClinicalTrials.gov , NCT02163759 (HIBISCUS I), NCT02171429 (HIBISCUS II). Findings Between Nov 4, 2014, and May 25, 2020, each study screened 652 patients (HIBISCUS I) and 613 patients (HIBISCUS II). Each study enrolled and randomly assigned 358 patients (HIBISCUS I etrolizumab n=144, adalimumab n=142, placebo n=72; HIBISCUS II etrolizumab n=143; adalimumab n=143; placebo n=72). In HIBISCUS I, 28 (19·4%) of 144 patients in the etrolizumab group and five (6·9%) of 72 patients in the placebo group were in remission at week 10, with an adjusted treatment difference of 12·3% (95% CI 1·6 to 20·6; p=0·017) in favour of etrolizumab. In HIBISCUS II, 26 (18·2%) of 143 patients in the etrolizumab group and eight (11·1%) of 72 patients in the placebo group were in remission at week 10, with an adjusted treatment difference of 7·2% (95% CI –3·8 to 16·1; p=0·17). In the pooled analysis, etrolizumab was not superior to adalimumab for induction of remission, endoscopic improvement, clinical response, histological remission, or endoscopic remission; however, similar numerical results were observed in both groups. In HIBISCUS I, 50 (35%) of 144 patients in the etrolizumab group reported any adverse event, compared with 61 (43%) of 142 in the adalimumab group and 26 (36%) of 72 in the placebo group. In HIBISCUS II, 63 (44%) of 143 patients in the etrolizumab group reported any adverse event, as did 62 (43%) of 143 in the adalimumab group and 33 (46%) in the placebo group. The most common adverse event in all groups was ulcerative colitis flare. The incidence of serious adverse events in the pooled patient population was similar for etrolizumab (15 [5%] of 287) and placebo (seven [5%] of 144) and lower for adalimumab (six [2%] of 285). Two patients in the etrolizumab group died; neither death was deemed to be treatment related. Interpretation Etrolizumab was superior to placebo for induction of remission in HIBISCUS I, but not in HIBISCUS II. Etrolizumab was well tolerated in both studies. Funding F Hoffmann-La Roche.

Published
2021

129. Timucua Hand Use: Dispelling the Myth of Left-Hand Preference

Author

George Aaron Broadwell

Subjects
Property (philosophy), Hand preference, Argument, Linguistic evidence, Hand use, Mythology, Positive economics, Psychology, Preference
Abstract

At the time of Spanish contact, the Timucua were the original people of northern central Florida. Granberry (1996) claimed in a provocative article that Timucua constitutes an exception to the universal or near-universal property of preference for the right hand, and showed a preference for the left hand instead. This article critically examines Granberry's argument, and shows that there is no good linguistic evidence to support left-hand preference in Timucua

Published
2021
Full Text
View/download PDF

131. The physician-patient relationship has changed. Physicians must change with it

Author

George, Aaron

Subjects
Physicians -- Services, Physician-patient relations -- Analysis, Health care industry, Telemedicine, Ambulatory care facilities, Business, Economics, Health care industry
Abstract

Is the patient-physician relationship evolving or eroding? The dynamic between patient and physician is in the midst of massive transformation, shifting as rapidly as the health systems surrounding it. This [...]

Published
2019

133. Two-Dimensional Van der Waals Materials for Thin Film Transistor Applications

Author

George, Aaron

Subjects
Nanoscience, Engineering, Materials Science, Block copolymer, Chemical vapor deposition, Field-effect transistors, Graphene, Molybdenum Disulfide
Abstract

Research on two-dimensional nanomaterials has become a topic of considerable interest since the pioneering work experimentally introducing the two-dimensional carbon allotrope of graphene in 2004. The atomically thin hexagonally arranged carbon crystal structure has offered the opportunity for numerous studies in condensed matter physics and materials science, revealing new phenomenon and remarkable properties. Graphene has excellent chemical and mechanical stability, allowing researchers to probe the properties of graphene in a wide variety of applications and in contact with a wide variety of materials. Ballistic transport of graphene at room temperature suggests that graphene would be poised to enter in to a wide variety of microelectronic application;viihowever, synthesis methods and surface effects have so far limited the widespread use of graphene. Additionally, the absence of electronic band gap in graphene, classifying it as a "semi-metal", limits the use of graphene to areas other than logic applications.In this work, fabrication methods for the improved synthesis graphene and selected two-dimensional transition metal dichalcogenides, molybdenum disulfide and tungsten disulfide, are presented for thin film transistor applications. First, the introduction of thin film zwitterionic polymer interlayers in graphene devices is outlined as a means to reduce the contact resistance between metal contacts and the underlying graphene layer. Second, a self-assembly nanoscale lithography process utilizing diblock copolymer templates as an etching mask directly on the surface of graphene is shown as a method to introduce a band gap in graphene due to quantum confinement effects. The third chapter applies to another class of two-dimensional materials, transition metal dichalcogenides, which, unlike graphene, can exhibit suitable electronic band structures for logic applications. When the thickness of these transition metal dichalcogenides is reduced to a single atomic layer, electronic band states transition from an indirect band gap to a direct band gap. A wafer-scale method for the synthesis of atomically thin transition metal dichalcogenides by the thermolysis of spin coated precursors is introduced which holds promise for next-generation low-power consumption applications.

Published
2014

138. The apple tree community.

Author

Smith, George Aaron, 1896- [fr, Prelinger Library (archive.org), and Smith, George Aaron, 1896- [fr

Subjects
Animal behavior, Pennsylvania, Zoology
Published
1960

139. Influence and Power in Group Interactions

Author

Strzalkowski, Tomek, primary, Shaikh, Samira, additional, Liu, Ting, additional, Broadwell, George Aaron, additional, Stromer-Galley, Jenny, additional, Taylor, Sarah, additional, Ravishankar, Veena, additional, Boz, Umit, additional, and Ren, Xiaoai, additional

Published
2013
Full Text
View/download PDF

141. Hypothyroidism Complicated by Vitamin C and Thiamin Deficiency in Surgical Patients

Author

Bonatti, Hugo J. R., Gona, Sridhar Rao, Feaga, Catherine, and George, Aaron E.

Abstract

Multiple vitamin deficiencies together with endocrinopathy may be encountered in individuals presenting with critical illness. Following the surprise postmortem diagnosis of concomitant scurvy, Wernicke, and hypothyroidism in an elderly woman presenting with a mix of atypical symptoms, patients considered at risk were tested for TSH, vitamin C, and thiamin levels. Between September 1, 2018, and December 31, 2022, 801 vitamin C levels in 679 patients were measured in our rural hospital and 309 (39%) were found <0.4 mg/dL. In this population, 39% of 626 thiamin levels were found to be low. Twenty-two patients with vitamin C and/or thiamin deficiency and elevated TSH levels were identified. Two patients died from scurvy; one also had myxedema. The incidence of vitamin C and thiamin deficiency in our patient population was higher than expected. Further studies should determine if this is unique to our rural setting or part of a bigger trend associated with poor dietary choices.

Published
2023
Full Text
View/download PDF

149. A young physician's view on EHRs: They don't work well enough

Author

George, Aaron

Subjects
Physician and patient -- Analysis, Physicians -- Practice -- Beliefs, opinions and attitudes, Medical colleges -- Management -- Analysis, Electronic records -- Management -- Analysis, Company business management, Business, Economics, Health care industry
Abstract

In the brief span of my medical school and residency training I was exposed to 16 different electronic health records (EHRs), as well as paper charting. Ironically, I found that [...]

Published
2018

150. Toby Cosgrove heads to Google: What does his move mean for digital healthcare?

Author

George, Aaron

Subjects
Company business planning, Medical economics -- Analysis, Veterans -- Evaluation -- Analysis -- Planning, Medical advice systems -- Planning -- Evaluation, Medical care -- Analysis
Abstract

When Delos "Toby" Cosgrove, MD, stepped down from the helm of Cleveland Clinic, where he had served as chief executive officer since 2004, few thought he was ready to exit [...]

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results